SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions.
"I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to innovate, Deb's addition to our leadership team will be vital in moving our company forward and achieving our goals," said Norbert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio, Inc.
"I am thrilled to be joining Kronos Bio at a pivotal time in the company's trajectory. With a discovery platform that has already produced two internally discovered ...